Nautilus Biotechnology Inc Overview
Industry: Biotechnology
Sector: Healthcare
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was incorporated in 2016 and is headquartered in Seattle, Washington. Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumable Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Nautilus Biotechnology Inc into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $0.2M (reported). Net loss was -$14.5M. Cash was $129.2M.
Revenue
$0.2M
reported
Net loss
-$14.5M
reported
Cash
$129.2M
reported
What changed
- Revenue reported to $0.2M.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
8-K
Jul 28, 2026
SEC filing
10-Q
Jul 28, 2026
SEC filing
10-Q
Apr 28, 2026
SEC filing
8-K
Apr 28, 2026
Earnings release
Earnings release
Apr 28, 2026
SEC filing
10-K
Feb 26, 2026
SEC filing
8-K
Feb 26, 2026
Earnings release
Earnings release
Feb 26, 2026
Earnings release
Earnings release
Oct 28, 2025
SEC filing
8-K
Oct 28, 2025
SEC filing
10-Q
Oct 28, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Nautilus Biotechnology: A Contrarian Proteoformics Play After Recent Pullback (NAUT)
Headline from Seeking Alpha: Nautilus Biotechnology: A Contrarian Proteoformics Play After Recent Pullback (NAUT).
Earnings Per Share
Score 1.00/5
Nautilus Biotechnology Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Biotechnology industry
, Halozyme Therapeutics Inc
, Corcept Therapeutics Incorporated
, Exelixis Inc
are companies with high ratings.
Return on Equity
Score 0.84/5
Nautilus Biotechnology Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 2.21/5
Nautilus Biotechnology Inc
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 3.88/5
Nautilus Biotechnology Inc
attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
, also exhibit high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios